Fatemeh Varshoee Tabrizi
Overview
Explore the profile of Fatemeh Varshoee Tabrizi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zahedi F, Jafari A, Nasiri Motlagh B, Hamedi S, Salek R, Khandoozi S, et al.
Expert Opin Drug Saf
. 2024 Jul;
:1-6.
PMID: 39076099
Background: Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). This post-marketing surveillance evaluates the safety of a trastuzumab biosimilar (AryoTrust), produced by AryoGen...
2.
Abdollahi S, Mowlavi A, Yazdi M, Ceberg S, Aznar M, Varshoee Tabrizi F, et al.
Phys Imaging Radiat Oncol
. 2024 May;
30:100587.
PMID: 38818304
Background And Purpose: Motion management techniques are important to spare the healthy tissue adequately. However, they are complex and need dedicated quality assurance. The aim of this study was to...
3.
Abdollahi S, Yazdi M, Mowlavi A, Ceberg S, Aznar M, Varshoee Tabrizi F, et al.
Rep Pract Oncol Radiother
. 2023 Oct;
28(3):435.
PMID: 37795401
[This corrects the article DOI: 10.5603/RPOR.a2022.0103.].
4.
Abdollahi S, Yazdi M, Mowlavi A, Ceberg S, Aznar M, Varshoee Tabrizi F, et al.
Tech Innov Patient Support Radiat Oncol
. 2023 Feb;
25:100201.
PMID: 36798947
Purpose: To investigate the possibility to be able to offer left sided breast cancer patients, not suitable for DIBH, an organ at risk saving treatment. Materials And Methods: Twenty patients...
5.
Abdollahi S, Yazdi M, Mowlavi A, Ceberg S, Aznar M, Varshoee Tabrizi F, et al.
Rep Pract Oncol Radiother
. 2022 Dec;
27(5):881-896.
PMID: 36523810
Background: The aim of the study is to evaluate the overall accuracy of the surface-guided radiotherapy (SGRT) workflow through a comprehensive commissioning and quality assurance procedures and assess the potential...
6.
Movahed S, Varshoee Tabrizi F, Pahlavani N, Toussi M, Motlagh A, Eslami S, et al.
Clin Nutr
. 2021 Jan;
40(6):4449-4455.
PMID: 33509666
Background & Aims: Malnutrition is prevalent in upper gastrointestinal cancer patients. The purpose of this study was a comprehensive assessment of nutritional status in newly diagnosed patients with esophageal cancer....
7.
Movahed S, Norouzy A, Ghanbari-Motlagh A, Eslami S, Khadem-Rezaiyan M, Emadzadeh M, et al.
Asian Pac J Cancer Prev
. 2020 Aug;
21(8):2315-2323.
PMID: 32856860
Background: Malnutrition is prevalent in esophageal cancer patients which affects cancer prognosis. The purpose of this study was a comprehensive assessment of nutritional status during Chemoradiation (CRT). Methods: Newly diagnosed...
8.
Mojtabanezhad Shariatpanahi A, Rokni P, Shahabi E, Varshoee Tabrizi F, Kerachian M
BMC Res Notes
. 2018 Oct;
11(1):757.
PMID: 30352614
Objective: In the present study, we investigated different simple and cost effective methods to evaluate and validate cell free DNA (cfDNA) isolation. The ability of the QIAamp DNA Blood Mini...
9.
Mojtabanezhad Shariatpanahi A, Yassi M, Nouraie M, Sahebkar A, Varshoee Tabrizi F, Kerachian M
PLoS One
. 2018 Jul;
13(7):e0200735.
PMID: 30024936
A large number of tumor-related methylated genes have been suggested to be of diagnostic and prognostic values for CRC when analyzed in patients' stool samples; however, reported sensitivities and specificities...
10.
Nariman-Saleh-Fam Z, Bastami M, Somi M, Behjati F, Mansoori Y, Daraei A, et al.
Genet Test Mol Biomarkers
. 2017 Apr;
21(6):382-390.
PMID: 28430524
Aims: Iran is located in the Asian esophageal cancer belt. It is a high-risk region for esophageal squamous cell carcinoma (ESCC). The extent to which genetic components, especially variants within...